• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Milton C. Weinstein, PhD


  • Lubitz CC, Kong CY, McMahon PM, Daniels GH, Chen Y, Economopoulos KP, Gazelle GS, Weinstein MC.Annual financial impact of well-differentiated thyroid cancer care in the United States.Cancer. 2014 May 1;120(9):1345-52.
  • Fust K, Li X, Maschio M, Barron R, Weinstein MC, Parthan A, Walli-Attaei M, Chandler DB, Lyman GH.Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.Gynecol Oncol. 2014 Mar 19.
  • Hill G, Barron R, Fust K, Skornicki ME, Taylor DC, Weinstein MC, Lyman GH.Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.J Med Econ. 2014 Jan;17(1):32-42.
  • Lawrence D, Maschio M, Leahy KJ, Yunger S, Easaw JC, Weinstein MC.Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).J Med Econ. 2013 Dec;16(12):1387-98.
  • McMahon PM, Kong CY, Johnson BE, Weinstein MC, Weeks JC, Tramontano AC, Cipriano LE, Bouzan C, Gazelle GS.Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening.Risk Anal. 2012 Jul;32 Suppl 1:S117-24.
  • Groot Koerkamp B, Stijnen T, Weinstein MC, Hunink MG.The Combined Analysis of Uncertainty and Patient Heterogeneity in Medical Decision Models.Med Decis Making. 2010 Oct 25.
  • Neumann PJ, Weinstein MC.Legislating against use of cost-effectiveness information.N Engl J Med. 2010 Oct 14;363(16):1495-7.
  • Taylor DC, Pawar V, Kruzikas D, Gilmore KE, Pandya A, Iskandar R, Weinstein MC.Methods of model calibration: observations from a mathematical model of cervical cancer.Pharmaco Economics. 2010 Nov 1;28(11):995-1000.
  • Groot Koerkamp B, Weinstein MC, Stijnen T, Heijenbrok-Kal MH, Hunink MG.Uncertainty and Patient Heterogeneity in Medical Decision Models.Med Decis Making.;30(2):194-205.
  • Weinstein MC, Skinner JA.Comparative effectiveness and health care spending--implications for reform.N Engl J Med. 2010 Feb 4;362(5):460-5.
  • Ladapo JA, Jaffer FA, Hoffmann U, Thomson CC, Bamberg F, Dec W, Cutler DM, Weinstein MC, Gazelle GS.Clinical outcomes and cost-effectiveness of coronary computed tomography angiography in the evaluation of patients with chest pain.J Am Coll Cardiol. 2009 Dec 15;54(25):2409-22.
  • Bentley TG, Weinstein MC, Kuntz KM.Effects of categorizing continuous variables in decision-analytic models.Med Decis Making.;29(5):549-56.
  • Ladapo JA, Horwitz JR, Weinstein MC, Gazelle GS, Cutler DM.Adoption and spread of new imaging technology: a case study.Health Aff (Millwood).;28(6):w1122-32.
  • Ruger JP, Emmons KM, Kearney MH, Weinstein MC.Measuring the costs of outreach motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women.BMC Pregnancy Childbirth. 2009;9:46.
  • O'Sullivan AK, Pandya A, Papadopoulos G, Thompson D, Langston A, Perfect J, Weinstein MC.Cost-Effectiveness of Posaconazole versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infections among Neutropenic Patients in the United States.Value Health. 2009 Jan 9.
  • O'Sullivan AK,Thompson D,Chu P,Lee DW,Stewart EA,Weinstein MC.Cost-effectiveness of magnetic resonance guided focused ultrasound for the treatment of uterine fibroids.Int J Technol Assess Health Care. 2009 Jan;25(1):14-25.
  • McMahon PM, Kong CY, Weinstein MC, Tramontano AC, Cipriano LE, Johnson BE, Weeks JC, Gazelle GS.Adopting helical CT screening for lung cancer : potential health consequences during a 15-year period.Cancer. 2008 Dec 15;113(12):3440-9.
  • Ciaranello AL,Seage GR 3rd,Freedberg KA,Weinstein MC,Lockman S,Walensky RP.Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity.AIDS. 2008 Nov 12;22(17):2359-69.
  • Walensky RP,Freedberg KA,Weinstein MC.Monitoring of antiretroviral therapy in low-resource settings.Lancet. 2008 Jul 26;372(9635):288; author reply 289.
  • Bentley TG,Weinstein MC,Willett WC,Kuntz KM.A cost-effectiveness analysis of folic acid fortification policy in the United States.Public Health Nutr. 2009 Apr;12(4):455-67.
  • McMahon PM, Kong CY, Johnson BE, Weinstein MC, Weeks JC, Kuntz KM, Shepard JA, Swensen SJ, Gazelle GS.Estimating Long-term Effectiveness of Lung Cancer Screening in the Mayo CT Screening Study.Radiology. 2008 Jul;248(1):278-87.
  • Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC.Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data.Value Health. 2008 Mar-Apr;11(2):213-20.
  • Weinstein MC.How much are Americans willing to pay for a quality-adjusted life year?.Med Care. 2008 Apr;46(4):343-5.
  • Lee JM, Kopans DB, McMahon PM, Halpern EF, Ryan PD, Weinstein MC, Gazelle GS.Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis.Radiology. 2008 Mar;246(3):763-71.
  • Cohen JT, Neumann PJ, Weinstein MC.Does preventive care save money? Health economics and the presidential candidates.N Engl J Med. 2008 Feb 14;358(7):661-3.
  • Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD.Cost-effectiveness of HIV testing and treatment in the United States.Clin Infect Dis. 2007 Dec 15;45 Suppl 4:S248-54. Review.
  • Chan DC, Heidenreich PA, Weinstein MC, Fonarow GC.Heart failure disease management programs: a cost-effectiveness analysis.Am Heart J. 2008 Feb;155(2):332-8.
  • Freedberg KA, Kumarasamy N, Losina E, Cecelia AJ, Scott CA, Divi N, Flanigan TP, Lu Z, Weinstein MC, Wang B, Ganesh AK, Bender MA, Mayer KH, Walensky RP.Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.AIDS. 2007 Jul;21 Suppl 4:S117-28.
  • Thompson D, Taylor DC, Montoya EL, Winer EP, Jones SE, Weinstein MC.Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer.Value Health. 2007 Sep-Oct;10(5):367-76.
  • Schackman BR, Scott CA, Sax PE, Losina E, Wilkin TJ, McKinnon JE, Swindells S, Weinstein MC, Freedberg KA.Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial.Clin Infect Dis. 2007 Oct 15;45(8):1062-70.
  • Ruger JP, Weinstein MC, Hammond SK, Kearney MH, Emmons KM.Cost-effectiveness of motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women: a randomized controlled trial.Value Health. 2008 Mar-Apr;11(2):191-8.
  • Yazdanpanah Y, Vray M, Meynard J, Losina E, Weinstein MC, Morand-Joubert L, Goldie SJ, Hsu HE, Walensky RP, Dalban C, Sax PE, Girard PM, Freedberg KA.The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach.HIV Med. 2007 Oct;8(7):439-50.
  • Walensky RP, Weinstein MC, Yazdanpanah Y, Losina E, Mercincavage LM, Touré S, Divi N, Anglaret X, Goldie SJ, Freedberg KA,.HIV drug resistance surveillance for prioritizing treatment in resource-limited settings.AIDS. 2007 May 11;21(8):973-82.
  • Groot Koerkamp B, Hunink MG, Stijnen T, Hammitt JK, Kuntz KM, Weinstein MC.Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.Med Decis Making. 2007 Mar-Apr;27(2):101-11.
  • McCormick AW, Walensky RP, Lipsitch M, Losina E, Hsu H, Weinstein MC, Paltiel AD, Freedberg KA, Seage GR.The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men.Clin Infect Dis. 2007 Apr 15;44(8):1115-22.
  • Schackman BR, Freedberg KA, Goldie SJ, Weinstein MC, Swartz K.Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment.Health Care Financ Rev. 2005 Summer;26(4):67-80.
  • Aballéa S, Chancellor JV, Raikou M, Drummond MF, Weinstein MC, Jourdan S, Bridgewater J.Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.Cancer. 2007 Mar 15;109(6):1082-9.
  • Paltiel AD, Walensky RP, Schackman BR, Seage GR, Mercincavage LM, Weinstein MC, Freedberg KA.Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.Ann Intern Med. 2006 Dec 5;145(11):797-806.
  • Freedberg KA, Hirschhorn LR, Schackman BR, Wolf LL, Martin LA, Weinstein MC, Goldin S, Paltiel AD, Katz C, Goldie SJ, Losina E.Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients.J Acquir Immune Defic Syndr. 2006 Dec 1;43 Suppl 1:S113-8.
  • Kim JJ, Salomon JA, Weinstein MC, Goldie SJ.Packaging health services when resources are limited: the example of a cervical cancer screening visit.PLoS Med. 2006 Nov;3(11):e434.
  • Weinstein MC.Recent developments in decision-analytic modelling for economic evaluation.Pharmacoeconomics. 2006;24(11):1043-53. Review.
  • Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage GR, Moore RD, Freedberg KA.The lifetime cost of current human immunodeficiency virus care in the United States.Med Care. 2006 Nov;44(11):990-7. Review.
  • Bentley TG, Willett WC, Weinstein MC, Kuntz KM.Population-level changes in folate intake by age, gender, and race/ethnicity after folic acid fortification.Am J Public Health. 2006 Nov;96(11):2040-7.
  • McMahon PM, Zaslavsky AM, Weinstein MC, Kuntz KM, Weeks JC, Gazelle GS.Estimation of mortality rates for disease simulation models using Bayesian evidence synthesis.Med Decis Making. 2006 Sep-Oct;26(5):497-511.
  • Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, Hsu HE, Kimmel A, Holmes C, Kaplan JE, Freedberg KA.Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.N Engl J Med. 2006 Sep 14;355(11):1141-53.
  • Gaziano TA, Opie LH, Weinstein MC.Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis.Lancet. 2006 Aug 19;368(9536):679-86. Review.
  • Losina E, Anglaret X, Yazdanpanah Y, Wang B, Toure S, Seage GR, N'Dri-Yoman T, Walensky RP, Dakoury-Dogbo N, Goldie SJ, Messou E, Weinstein MC, Deuffic-Burban S, Salamon R, Freedberg KA.Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Côte d'Ivoire.S Afr Med J. 2006 Jun;96(6):526-9.
  • Resch SC, Salomon JA, Murray M, Weinstein MC.Cost-effectiveness of treating multidrug-resistant tuberculosis.PLoS Med. 2006 Jul;3(7):e241.
  • Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, Weinstein MC, Freedberg KA.The survival benefits of AIDS treatment in the United States.J Infect Dis. 2006 Jul 1;194(1):11-9.
  • Kim SY, Billah K, Lieu TA, Weinstein MC.Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites.Am J Prev Med. 2006 Jun;30(6):498-506.
  • Zupancic JA, Richardson DK, O'Brien BJ, Cronin CG, Schmidt B, Roberts R, Weinstein MC,.Retrospective economic evaluation of a controlled trial of indomethacin prophylaxis for patent ductus arteriosus in premature infants.Early Hum Dev. 2006 Feb;82(2):97-103.
  • Neumann PJ, Lin PJ, Greenberg D, Berger M, Teutsch S, Mansley E, Weinstein MC, Rosen AB.Do drug formulary policies reflect evidence of value?.Am J Manag Care. 2006 Jan;12(1):30-6.
  • Groot Koerkamp B, Myriam Hunink MG, Stijnen T, Weinstein MC.Identifying key parameters in cost-effectiveness analysis using value of information: a comparison of methods.Health Econ. 2006 Apr;15(4):383-92.
  • Gaziano TA, Steyn K, Cohen DJ, Weinstein MC, Opie LH.Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level.Circulation. 2005 Dec 6;112(23):3569-76.
  • Neumann PJ, Rosen AB, Weinstein MC.Medicare and cost-effectiveness analysis.N Engl J Med. 2005 Oct 6;353(14):1516-22.
  • Sax PE, Islam R, Walensky RP, Losina E, Weinstein MC, Goldie SJ, Sadownik SN, Freedberg KA.Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis.Clin Infect Dis. 2005 Nov 1;41(9):1316-23.
  • Elkin EB, Weinstein MC, Kuntz KM, Bunnell CA, Weeks JC.Adjuvant ovarian suppression versus chemotherapy for premenopausal, hormone-responsive breast cancer: quality of life and efficacy tradeoffs.Breast Cancer Res Treat. 2005 Sep;93(1):25-34.
  • Neumann PJ, Rosen AB, Greenberg D, Olchanski NV, Pande R, Chapman RH, Stone PW, Ondategui-Parra S, Nadai J, Siegel JE, Weinstein MC.Can we better prioritize resources for cost-utility research?.Med Decis Making. 2005 Jul-Aug;25(4):429-36.
  • Yazdanpanah Y, Losina E, Anglaret X, Goldie SJ, Walensky RP, Weinstein MC, Toure S, Smith HE, Kaplan JE, Freedberg KA,.Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis.AIDS. 2005 Aug 12;19(12):1299-308.
  • Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S.Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.Ann Intern Med. 2005 Jul 19;143(2):89-99.
  • Aledort JE, Hook EW, Weinstein MC, Goldie SJ.The cost effectiveness of gonorrhea screening in urban emergency departments.Sex Transm Dis. 2005 Jul;32(7):425-36.
  • Walensky RP, Weinstein MC, Smith HE, Freedberg KA, Paltiel AD.Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral.Med Decis Making. 2005 May-Jun;25(3):321-9.
  • Sax PE, Losina E, Weinstein MC, Paltiel AD, Goldie SJ, Muccio TM, Kimmel AD, Zhang H, Freedberg KA, Walensky RP.Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease.J Acquir Immune Defic Syndr. 2005 May 1;39(1):69-77.
  • Sinha A, Lieu TA, Paoletti LC, Weinstein MC, Platt R.The projected health benefits of maternal group B streptococcal vaccination in the era of chemoprophylaxis.Vaccine. 2005 May 2;23(24):3187-95.
  • Kimmel AD, Goldie SJ, Walensky RP, Losina E, Weinstein MC, Paltiel AD, Zhang H, Freedberg KA,.Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.Antivir Ther. 2005;10(1):41-52.
  • Walensky RP, Weinstein MC, Kimmel AD, Seage GR, Losina E, Sax PE, Zhang H, Smith HE, Freedberg KA, Paltiel AD.Routine human immunodeficiency virus testing: an economic evaluation of current guidelines.Am J Med. 2005 Mar;118(3):292-300.
  • Paltiel AD, Weinstein MC, Kimmel AD, Seage GR, Losina E, Zhang H, Freedberg KA, Walensky RP.Expanded screening for HIV in the United States--an analysis of cost-effectiveness.N Engl J Med. 2005 Feb 10;352(6):586-95.
  • Teutsch SM, Berger ML, Weinstein MC.Comparative effectiveness: asking the right questions, choosing the right method.Health Aff (Millwood). 2005 Jan-Feb;24(1):128-32.
  • Rinfret S, Cohen DJ, Lamas GA, Fleischmann KE, Weinstein MC, Orav J, Schron E, Lee KL, Goldman L.Cost-effectiveness of dual-chamber pacing compared with ventricular pacing for sinus node dysfunction.Circulation. 2005 Jan 18;111(2):165-72.
  • Gazelle GS, McMahon PM, Beinfeld MT, Halpern EF, Weinstein MC.Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection.Radiology. 2004 Dec;233(3):729-39.
  • McGarry LJ, Thompson D, Weinstein MC, Goldhaber SZ.Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients.Am J Manag Care. 2004 Sep;10(9):632-42.
  • Salomon JA, Weinstein MC, Goldie SJ.Taking account of future technology in cost effectiveness analysis.BMJ. 2004 Sep 25;329(7468):733-6.
  • Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC.Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.Value Health. 2004 Sep-Oct;7(5):554-68.
  • Walensky RP, Paltiel AD, Goldie SJ, Gandhi RT, Weinstein MC, Seage GR, Smith HE, Zhang H, Freedberg KA.A therapeutic HIV vaccine: how good is good enough?.Vaccine. 2004 Sep 28;22(29-30):4044-53.
  • Elstein AS, Fryback DG, Weinstein MC, Pauker SG, Holmes-Rovner M, Young MJ, Barry MJ, Eckman MH, Hunink MG, Tsevat J, Wong JB.Presidential reflections on the 25th anniversary of the society for medical decision making.Med Decis Making. 2004 Jul-Aug;24(4):408-20.
  • Chapman RH, Berger M, Weinstein MC, Weeks JC, Goldie S, Neumann PJ.When does quality-adjusting life-years matter in cost-effectiveness analysis?.Health Econ. 2004 May;13(5):429-36.
  • Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E.Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.J Natl Cancer Inst. 2004 Apr 21;96(8):604-15.
  • Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC.HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.J Clin Oncol. 2004 Mar 1;22(5):854-63.
  • Marshall DA, Kleinman SH, Wong JB, AuBuchon JP, Grima DT, Kulin NA, Weinstein MC.Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States.Vox Sang. 2004 Jan;86(1):28-40.
  • Amorosi SL, Tsilimingras K, Thompson D, Fanikos J, Weinstein MC, Goldhaber SZ.Cost analysis of "bridging therapy" with low-molecular-weight heparin versus unfractionated heparin during temporary interruption of chronic anticoagulation.Am J Cardiol. 2004 Feb 15;93(4):509-11.
  • Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR, Kimmel AD, Walensky RP, Sax PE, Freedberg KA.Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection.Am J Med. 2003 Dec 1;115(8):632-41.
  • Weinstein MC.Coronary artery bypass surgery is still cost-effective: using calibrated models to update clinical trials.Am J Med. 2003 Oct 1;115(5):410-1.
  • Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E.A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine.Int J Cancer. 2003 Oct 10;106(6):896-904.
  • Lieu TA, Thompson KM, Prosser LA, O'Brien MA, Yusuf HR, Shefer AM, Weinstein MC, Rickert DL.Emerging issues in vaccine economics: perspectives from the USA.Expert Rev Vaccines. 2002 Dec;1(4):433-42.
  • Zupancic JA, Richardson DK, O'Brien BJ, Schmidt B, Weinstein MC.Daily cost prediction model in neonatal intensive care.Int J Technol Assess Health Care. 2003 Spring;19(2):330-8.
  • Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ.Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.JAMA. 2003 Jul 9;290(2):228-37.
  • Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC.Patient and community preferences for treatments and health states in multiple sclerosis.Mult Scler. 2003 Jun;9(3):311-9.
  • Gazelle GS, Hunink MG, Kuntz KM, McMahon PM, Halpern EF, Beinfeld M, Lester JS, Tanabe KK, Weinstein MC.Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis.Ann Surg. 2003 Apr;237(4):544-55.
  • Yazdanpanah Y, Goldie SJ, Losina E, Weinstein MC, Lebrun T, Paltiel AD, Seage GR, Leblanc G, Ajana F, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA.Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy.Antivir Ther. 2002 Dec;7(4):257-66.
  • Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR,.Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.Value Health. 2003 Jan-Feb;6(1):9-17.
  • Zupancic JA, Richardson DK, O'Brien BJ, Eichenwald EC, Weinstein MC.Cost-effectiveness analysis of predischarge monitoring for apnea of prematurity.Pediatrics. 2003 Jan;111(1):146-52.
  • Yazdanpanah Y, Goldie SJ, Paltiel AD, Losina E, Coudeville L, Weinstein MC, Gerard Y, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA.Prevention of human immunodeficiency virus related opportunistic infections in France: A cost-effectiveness analysis.Clin Infect Dis. 2003;36(1):86-96.
  • McGarry LJ, Thompson D, Millham FH, Cowell L, Snyder PJ, Lenderking WR, Weinstein MC.Outcomes and costs of acute treatment of traumatic brain injury.J Trauma. 2002 Dec;53(6):1152-9.
  • Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC.The relationship between risk attitude and treatment choice in patients with relapsing-remitting multiple sclerosis.Med Decis Making. 2002 Nov-Dec;22(6):506-13.
  • Schackman BR, Freedberg KA, Weinstein MC, Sax PE, Losina E, Zhang H, Goldie SJ.Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults.Arch Intern Med. 2002 Nov 25;162(21):2478-86.
  • Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS.Health economic evaluations: the special case of end-stage renal disease treatment.Med Decis Making. 2002 Sep-Oct;22(5):417-30.
  • Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ.Empirically calibrated model of hepatitis C virus infection in the United States.Am J Epidemiol. 2002 Oct 15;156(8):761-73.
  • Walensky RP, Goldie SJ, Sax PE, Weinstein MC, Paltiel AD, Kimmel AD, Seage GR, Losina E, Zhang H, Islam R, Freedberg KA.Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy.J Acquir Immune Defic Syndr. 2002 Sep 1;31(1):27-37.
  • Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J.Long-term persistence in use of statin therapy in elderly patients.JAMA. 2002 Jul 24-31;288(4):455-61.
  • Lieberfarb ME, Schultz D, Whittington R, Malkowicz B, Tomaszewski JE, Weinstein M, Wein A, Richie JP, D'Amico AV.Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy.Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):898-903.
  • Goldie SJ, Kaplan JE, Losina E, Weinstein MC, Paltiel AD, Seage GR, Craven DE, Kimmel AD, Zhang H, Cohen CJ, Freedberg KA.Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.Arch Intern Med. 2002 Apr 22;162(8):921-8.
  • Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks JC.Impact of referral patterns on the use of chemotherapy for lung cancer.J Clin Oncol. 2002 Apr 1;20(7):1786-92.
  • Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC.Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS.Med Decis Making. 2002 Jan-Feb;22(1):27-38.
  • Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS, Kuntz KM, Graham JD, Hammitt JK.Modeling for health care and other policy decisions: uses, roles, and validity.Value Health. 2001 Sep-Oct;4(5):348-61.
  • Goldman L, Phillips KA, Coxson P, Goldman PA, Williams L, Hunink MG, Weinstein MC.The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost.J Am Coll Cardiol. 2001 Oct;38(4):1012-7.
  • Schackman BR, Goldie SJ, Weinstein MC, Losina E, Zhang H, Freedberg KA.Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults.Am J Public Health. 2001 Sep;91(9):1456-63.
  • Tice JA, Ross E, Coxson PG, Rosenberg I, Weinstein MC, Hunink MG, Goldman PA, Williams L, Goldman L.Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond.JAMA. 2001 Aug 22-29;286(8):936-43.
  • Goldie SJ, Freedberg KA, Weinstein MC, Wright TC, Kuntz KM.Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus.Am J Med. 2001 Aug;111(2):140-9.
  • Weinstein MC.Should physicians be gatekeepers of medical resources?.J Med Ethics. 2001 Aug;27(4):268-74.
  • Claxton K, Neumann PJ, Araki S, Weinstein MC.Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease.Int J Technol Assess Health Care. 2001 Winter;17(1):38-55.
  • Tsevat J, Kuntz KM, Orav EJ, Weinstein MC, Sacks FM, Goldman L.Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels.Am Heart J. 2001 May;141(5):727-34.
  • Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter JD, Zhang H, Kimmel AD, Freedberg KA.Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.Ann Intern Med. 2001 Mar 20;134(6):440-50.
  • Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ.The cost effectiveness of combination antiretroviral therapy for HIV disease.N Engl J Med. 2001 Mar 15;344(11):824-31.
  • Paltiel AD, Goldie SJ, Losina E, Weinstein MC, Seage GR, Kimmel AD, Zhang H, Freedberg KA.Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus.Clin Infect Dis. 2001 Mar 1;32(5):783-93.
  • Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC.Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis.J Clin Oncol. 2001 Feb 15;19(4):1064-70.
  • Phillips KA, Shlipak MG, Coxson P, Heidenreich PA, Hunink MG, Goldman PA, Williams LW, Weinstein MC, Goldman L.Health and economic benefits of increased beta-blocker use following myocardial infarction.JAMA. 2000 Dec 6;284(21):2748-54.
  • Phillips KA, Shlipak MG, Coxson P, Heidenreich PA, Hunink MG, Goldman PA, Williams LW, Weinstein MC, Goldman L.Technical appendix.JAMA. 2000 Dec 6;284(21):2754A.
  • Neumann PJ, Sandberg EA, Araki SS, Kuntz KM, Feeny D, Weinstein MC.A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease.Med Decis Making. 2000 Oct-Dec;20(4):413-22.
  • Neumann PJ, Claxton K, Weinstein MC.The FDA's regulation of health economic information.Health Aff (Millwood). 2000 Sep-Oct;19(5):129-37.
  • Prosser LA, Koplan JP, Neumann PJ, Weinstein MC.Barriers to using cost-effectiveness analysis in managed care decision making.Am J Manag Care. 2000 Feb;6(2):173-9.
  • Halpern EF, Weinstein MC, Hunink MG, Gazelle GS.Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients.Med Decis Making. 2000 Jul-Sep;20(3):314-22.
  • Neumann PJ, Goldie SJ, Weinstein MC.Preference-based measures in economic evaluation in health care.Annu Rev Public Health. 2000;21:587-611.
  • Scharfstein JA, Paltiel AD, Weinstein MC, Seage GR, Losina E, Craven DE, Freedberg KA.The cost-effectiveness of prophylaxis for Mycobacterium avium complex in AIDS.Int J Technol Assess Health Care. 1999 Summer;15(3):531-47.
  • Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Palefsky JM.Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men.Am J Med. 2000 Jun 1;108(8):634-41.
  • Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC.Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.Ann Intern Med. 2000 May 16;132(10):769-79.
  • Earle CC, Venditti LN, Neumann PJ, Gelber RD, Weinstein MC, Potosky AL, Weeks JC.Who gets chemotherapy for metastatic lung cancer?.Chest. 2000 May;117(5):1239-46.
  • Mrus JM, Goldie SJ, Weinstein MC, Tsevat J.The cost-effectiveness of elective Cesarean delivery for HIV-infected women with detectable HIV RNA during pregnancy.AIDS. 2000 Nov 10;14(16):2543-52.
  • Kuntz KM, Tsevat J, Weinstein MC, Goldman L.Expert panel vs decision-analysis recommendations for postdischarge coronary angiography after myocardial infarction.JAMA. 1999 Dec 15;282(23):2246-51.
  • Weinstein MC.Theoretically correct cost-effectiveness analysis.Med Decis Making. 1999 Oct-Dec;19(4):381-2; discussion 383-4.
  • Goldman L, Coxson P, Hunink MG, Goldman PA, Tosteson AN, Mittleman M, Williams L, Weinstein MC.The relative influence of secondary versus primary prevention using the National Cholesterol Education Program Adult Treatment Panel II guidelines.J Am Coll Cardiol. 1999 Sep;34(3):768-76.
  • Neumann PJ, Kuntz KM, Leon J, Araki SS, Hermann RC, Hsu MA, Weinstein MC.Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers.Med Care. 1999 Jan;37(1):27-32.
  • Bosch JL, Hammitt JK, Weinstein MC, Hunink MG.Estimating general-population utilities using one binary-gamble question per respondent.Med Decis Making. 1998 Oct-Dec;18(4):381-90.
  • Weinstein MC.High-priced technology can be good value for money.Ann Intern Med. 1999 May 18;130(10):857-8.
  • Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM.The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men.JAMA. 1999 May 19;281(19):1822-9.
  • Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, Berenbaum PA, Goldman PA, Williams LW, Weinstein MC.Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease.Neurology. 1999 Apr 12;52(6):1138-45.
  • Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA.The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.Ann Intern Med. 1999 Jan 19;130(2):97-107.
  • Redelmeier DA, Weinstein MC.Cost-effectiveness of regulations against using a cellular telephone while driving.Med Decis Making. 1999 Jan-Mar;19(1):1-8.
  • Lee SJ, Liljas B, Neumann PJ, Weinstein MC, Johannesson M.The impact of risk information on patients' willingness to pay for autologous blood donation.Med Care. 1998 Aug;36(8):1162-73.
  • Wright JC, Weinstein MC.Gains in life expectancy from medical interventions--standardizing data on outcomes.N Engl J Med. 1998 Aug 6;339(6):380-6.
  • Hunink MG, Bult JR, de Vries J, Weinstein MC.Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method.Med Decis Making. 1998 Jul-Sep;18(3):337-46.
  • Graham JD, Corso PS, Morris JM, Segui-Gomez M, Weinstein MC.Evaluating the cost-effectiveness of clinical and public health measures.Annu Rev Public Health. 1998;19:125-52.
  • Tu JV, Weinstein MC, McNeil BJ, Naylor CD.Predicting mortality after coronary artery bypass surgery: what do artificial neural networks learn? The Steering Committee of the Cardiac Care Network of Ontario.Med Decis Making. 1998 Apr-Jun;18(2):229-35.
  • Gray DT, Weinstein MC.Decision and cost-utility analyses of surgical versus transcatheter closure of patent ductus arteriosus: should you let a smile be your umbrella?.Med Decis Making. 1998 Apr-Jun;18(2):187-201.
  • Paltiel AD, Scharfstein JA, Seage GR, Losina E, Goldie SJ, Weinstein MC, Craven DE, Freedberg KA.A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection.Med Decis Making. 1998 Apr-Jun;18(2 Suppl):S93-105.
  • Bult JR, Hunink MG, Tsevat J, Weinstein MC.Heterogeneity in the relationship between the time tradeoff and Short Form-36 for HIV-infected and primary care patients.Med Care. 1998 Apr;36(4):523-32.
  • Freedberg KA, Scharfstein JA, Seage GR, Losina E, Weinstein MC, Craven DE, Paltiel AD.The cost-effectiveness of preventing AIDS-related opportunistic infections.JAMA. 1998 Jan 14;279(2):130-6.
  • Lieu TA, Gurley RJ, Lundstrom RJ, Ray GT, Fireman BH, Weinstein MC, Parmley WW.Projected cost-effectiveness of primary angioplasty for acute myocardial infarction.J Am Coll Cardiol. 1997 Dec;30(7):1741-50.
  • Lee SJ, Kuntz KM, Horowitz MM, McGlave PB, Goldman JM, Sobocinski KA, Hegland J, Kollman C, Parsons SK, Weinstein MC, Weeks JC, Antin JH.Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis.Ann Intern Med. 1997 Dec 15;127(12):1080-8.
  • Neumann PJ, Hermann RC, Berenbaum PA, Weinstein MC.Methods of cost-effectiveness analysis in the assessment of new drugs for Alzheimer's disease.Psychiatr Serv. 1997 Nov;48(11):1440-4.
  • Graham JD, Thompson KM, Goldie SJ, Segui-Gomez M, Weinstein MC.The cost-effectiveness of air bags by seating position.JAMA. 1997 Nov 5;278(17):1418-25.
  • Weinstein MC, Siegel JE, Garber AM, Lipscomb J, Luce BR, Manning WG, Torrance GW.Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group.Health Econ. 1997 Sep-Oct;6(5):505-10.
  • Litvak E, Siegel JE, Pauker SG, Lallemant M, Fineberg HV, Weinstein MC.Whose blood is safer? The effect of the stage of the epidemic on screening for HIV.Med Decis Making. 1997 Oct-Dec;17(4):455-63.
  • Mandelblatt JS, Fryback DG, Weinstein MC, Russell LB, Gold MR.Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and Medicine.J Gen Intern Med. 1997 Sep;12(9):551-8.
  • Lee SJ, Neumann PJ, Churchill WH, Cannon ME, Weinstein MC, Johannesson M.Patients' willingness to pay for autologous blood donation.Health Policy. 1997 Apr;40(1):1-12.
  • Hunink MG, Goldman L, Tosteson AN, Mittleman MA, Goldman PA, Williams LW, Tsevat J, Weinstein MC.The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment.JAMA. 1997 Feb 19;277(7):535-42.
  • Weinstein MC, Manning WG.Theoretical issues in cost-effectiveness analysis.J Health Econ. 1997 Feb;16(1):121-8.
  • Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR.Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine.Pharmacoeconomics. 1997 Feb;11(2):159-68.
  • Tosteson AN, Weinstein MC, Hunink MG, Mittleman MA, Williams LW, Goldman PA, Goldman L.Cost-effectiveness of populationwide educational approaches to reduce serum cholesterol levels.Circulation. 1997 Jan 7;95(1):24-30.
  • Jönsson B, Weinstein MC.Economic evaluation alongside multinational clinical trials. Study considerations for GUSTO IIb.Int J Technol Assess Health Care. 1997 Winter;13(1):49-58.
  • Siegel JE, Weinstein MC, Russell LB, Gold MR.Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine.JAMA. 1996 Oct 23-30;276(16):1339-41.
  • Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB.Recommendations of the Panel on Cost-effectiveness in Health and Medicine.JAMA. 1996 Oct 16;276(15):1253-8.
  • Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC.The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine.JAMA. 1996 Oct 9;276(14):1172-7.
  • Kuntz KM, Tsevat J, Goldman L, Weinstein MC.Cost-effectiveness of routine coronary angiography after acute myocardial infarction.Circulation. 1996 Sep 1;94(5):957-65.
  • Coley CM, Li YH, Medsger AR, Marrie TJ, Fine MJ, Kapoor WN, Lave JR, Detsky AS, Weinstein MC, Singer DE.Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia.Arch Intern Med. 1996 Jul 22;156(14):1565-71.
  • Tengs TO, Meyer G, Siegel JE, Pliskin JS, Graham JD, Weinstein MC.Oregon's Medicaid ranking and cost-effectiveness: is there any relationship?.Med Decis Making. 1996 Apr-Jun;16(2):99-107.
  • Weinstein MC.Spine update.Spine. 1996 Mar 1;21(5):651-2.
  • Tsevat J, Solzan JG, Kuntz KM, Ragland J, Currier JS, Sell RL, Weinstein MC.Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning.Med Care. 1996 Jan;34(1):44-57.
  • Villari P, Fattore G, Siegel JE, Paltiel AD, Weinstein MC.Economic evaluation of HIV testing among intravenous drug users. An analytic framework and its application to Italy.Int J Technol Assess Health Care. 1996 Spring;12(2):336-57.
  • Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, Graham JD.Five-hundred life-saving interventions and their cost-effectiveness.Risk Anal. 1995 Jun;15(3):369-90.
  • Kuntz KM, Weinstein MC.Life expectancy biases in clinical decision modeling.Med Decis Making. 1995 Apr-Jun;15(2):158-69.
  • Revicki DA, Allen H, Bungay K, Williams GH, Weinstein MC.Responsiveness and calibration of the General Well-Being Adjustment Scale in patients with hypertension.J Clin Epidemiol. 1994 Dec;47(12):1333-42.
  • Gaspoz JM, Lee TH, Weinstein MC, Cook EF, Goldman P, Komaroff AL, Goldman L.Cost-effectiveness of a new short-stay unit to "rule out" acute myocardial infarction in low risk patients.J Am Coll Cardiol. 1994 Nov 1;24(5):1249-59.
  • Tosteson AN, Weinstein MC, Wittenberg J, Begg CB.ROC curve regression analysis: the use of ordinal regression models for diagnostic test assessment.Environ Health Perspect. 1994 Nov;102 Suppl 8:73-8.
  • Tsevat J, Weeks JC, Guadagnoli E, Tosteson AN, Mangione CM, Pliskin JS, Weinstein MC, Cleary PD.Using health-related quality-of-life information: clinical encounters, clinical trials, and health policy.J Gen Intern Med. 1994 Oct;9(10):576-82.
  • Neumann PJ, Gharib SD, Weinstein MC.The cost of a successful delivery with in vitro fertilization.N Engl J Med. 1994 Jul 28;331(4):239-43.
  • Paul SD, Kuntz KM, Eagle KA, Weinstein MC.Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure.Arch Intern Med. 1994 May 23;154(10):1143-9.
  • Cohen DJ, Breall JA, Ho KK, Kuntz RE, Goldman L, Baim DS, Weinstein MC.Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision-analytic model.Circulation. 1994 Apr;89(4):1859-74.
  • Johannesson M, Pliskin JS, Weinstein MC.A note on QALYs, time tradeoff, and discounting.Med Decis Making. 1994 Apr-Jun;14(2):188-93.
  • Gray DT, Fyler DC, Walker AM, Weinstein MC, Chalmers TC.Clinical outcomes and costs of transcatheter as compared with surgical closure of patent ductus arteriosus. The Patient Ductus Arteriosus Closure Comparative Study Group.N Engl J Med. 1993 Nov 18;329(21):1517-23.
  • Krumholz HM, Cohen BJ, Tsevat J, Pasternak RC, Weinstein MC.Cost-effectiveness of a smoking cessation program after myocardial infarction.J Am Coll Cardiol. 1993 Nov 15;22(6):1697-702.
  • Johannesson M, Weinstein MC.On the decision rules of cost-effectiveness analysis.J Health Econ. 1993 Dec;12(4):459-67.
  • Cohen DJ, Breall JA, Ho KK, Weintraub RM, Kuntz RE, Weinstein MC, Baim DS.Economics of elective coronary revascularization. Comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery.J Am Coll Cardiol. 1993 Oct;22(4):1052-9.
  • Johannesson M, Pliskin JS, Weinstein MC.Are healthy-years equivalents an improvement over quality-adjusted life years?.Med Decis Making. 1993 Oct-Dec;13(4):281-6.
  • Goldman L, Goldman PA, Williams LW, Weinstein MC.Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications.Am J Cardiol. 1993 Sep 30;72(10):75D-79D.
  • Weinstein MC.Time-preference studies in the health care context.Med Decis Making. 1993 Jul-Sep;13(3):218-9.
  • Siegel JE, Krolewski AS, Warram JH, Weinstein MC.Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus.J Am Soc Nephrol. 1992 Oct;3(4 Suppl):S111-9.
  • Goldman L, Weinstein MC.Reply to Kaplan: Coronary Heart Disease Policy Model.Am J Hypertens. 1992 Sep;5(9):666-9.
  • Krumholz HM, Pasternak RC, Weinstein MC, Friesinger GC, Ridker PM, Tosteson AN, Goldman L.Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction.N Engl J Med. 1992 Jul 2;327(1):7-13.
  • Goldman L, Gordon DJ, Rifkind BM, Hulley SB, Detsky AS, Goodman DW, Kinosian B, Weinstein MC.Cost and health implications of cholesterol lowering.Circulation. 1992 May;85(5):1960-8.
  • Capilouto EI, Weinstein MC, Hemenway D, Cotton D.What is the dentist's occupational risk of becoming infected with hepatitis B or the human immunodeficiency virus?.Am J Public Health. 1992 Apr;82(4):587-9.
  • Tosteson AN, Weinstein MC.Cost-effectiveness of hormone replacement therapy after the menopause.Baillieres Clin Obstet Gynaecol. 1991 Dec;5(4):943-59.
  • Siegel JE, Weinstein MC, Fineberg HV.Bleach programs for preventing AIDS among i.v. drug users: modeling the impact of HIV prevalence.Am J Public Health. 1991 Oct;81(10):1273-9.
  • Politser PE, Berwick DM, Murphy JM, Goldman PA, Weinstein MC.Uncovering psychiatric test information with graphical techniques of Exploratory Data Analysis.Psychiatry Res. 1991 Oct;39(1):65-79.
  • Weeks JC, Tierney MR, Weinstein MC.Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia.N Engl J Med. 1991 Jul 11;325(2):81-6.
  • Tsevat J, Weinstein MC, Williams LW, Tosteson AN, Goldman L.Expected gains in life expectancy from various coronary heart disease risk factor modifications.Circulation. 1991 Apr;83(4):1194-201.
  • Weinstein MC.The cost-effectiveness of orphan drugs.Am J Public Health. 1991 Apr;81(4):414-5.
  • Goldman L, Weinstein MC, Goldman PA, Williams LW.Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.JAMA. 1991 Mar 6;265(9):1145-51.
  • Berwick DM, Murphy JM, Goldman PA, Ware JE, Barsky AJ, Weinstein MC.Performance of a five-item mental health screening test.Med Care. 1991 Feb;29(2):169-76.
  • Hatziandreu EJ, Hatzakis A, Hatziyannis S, Kane MA, Weinstein MC.Cost-effectiveness of hepatitis-B vaccine in Greece. A country of intermediate HBV endemicity.Int J Technol Assess Health Care. 1991;7(3):256-62.
  • Tosteson AN, Weinstein MC, Williams LW, Goldman L.Long-term impact of smoking cessation on the incidence of coronary heart disease.Am J Public Health. 1990 Dec;80(12):1481-6.
  • Capilouto E, Weinstein MC, Orav EJ, Hemenway D.Modeling dental health care workers' risk of occupational infection from bloodborne pathogens.J Dent Educ. 1990 Nov;54(11):687-8.
  • Tosteson AN, Rosenthal DI, Melton LJ, Weinstein MC.Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy.Ann Intern Med. 1990 Oct 15;113(8):594-603.
  • Weinstein MC.The costs of prevention.J Gen Intern Med. 1990 Sep-Oct;5(5 Suppl):S89-92.
  • Anderson GM, Spitzer WO, Weinstein MC, Wang E, Blackburn JL, Bergman U.Benefits, risks, and costs of prescription drugs: a scientific basis for evaluating policy options.Clin Pharmacol Ther. 1990 Aug;48(2):111-9.
  • Weinstein MC, Coley CM, Richter JM.Medical management of gallstones: a cost-effectiveness analysis.J Gen Intern Med. 1990 Jul-Aug;5(4):277-84.
  • Edelson JT, Weinstein MC, Tosteson AN, Williams L, Lee TH, Goldman L.Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension.JAMA. 1990 Jan 19;263(3):407-13.
  • Weinstein MC.Principles of cost-effective resource allocation in health care organizations.Int J Technol Assess Health Care. 1990;6(1):93-103.
  • Weinstein MC, Tosteson AN.Cost-effectiveness of hormone replacement.Ann N Y Acad Sci. 1990;592:162-72; discussion 185-92.
  • Hatziandreu EE, Carlson K, Mulley AG, Weinstein MC.Cost-effectiveness study of the extracorporeal shock-wave lithotriptor.Int J Technol Assess Health Care. 1990;6(4):623-32.
  • White BA, Antczak-Bouckoms AA, Weinstein MC.Issues in the economic evaluation of community water fluoridation.J Dent Educ. 1989 Nov;53(11):646-57.
  • Weinstein MC.Methodologic issues in policy modeling for cardiovascular disease.J Am Coll Cardiol. 1989 Sep;14(3 Suppl A):38A-43A.
  • Goldman L, Weinstein MC, Williams LW.Relative impact of targeted versus populationwide cholesterol interventions on the incidence of coronary heart disease. Projections of the Coronary Heart Disease Policy Model.Circulation. 1989 Aug;80(2):254-60.
  • Weinstein MC, Berwick DM, Goldman PA, Murphy JM, Barsky AJ.A comparison of three psychiatric screening tests using receiver operating characteristic (ROC) analysis.Med Care. 1989 Jun;27(6):593-607.
  • Hatziandreu EI, Koplan JP, Weinstein MC, Caspersen CJ, Warner KE.A cost-effectiveness analysis of exercise as a health promotion activity.Am J Public Health. 1988 Nov;78(11):1417-21.
  • Lee TH, Fukui T, Weinstein MC, Tosteson AN, Goldman L.Cost-effectiveness of screening strategies for left main coronary artery disease in patients with stable angina.Med Decis Making. 1988 Oct-Dec;8(4):268-78.
  • Weinstein MC.A QALY is a QALY--or is it?.J Health Econ. 1988 Sep;7(3):289-90.
  • Goldman L, Sia ST, Cook EF, Rutherford JD, Weinstein MC.Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction.N Engl J Med. 1988 Jul 21;319(3):152-7.
  • Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L.Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model.Am J Public Health. 1987 Nov;77(11):1417-26.
  • Antczak-Bouckoms AA, Weinstein MC.Cost-effectiveness analysis of periodontal disease control.J Dent Res. 1987 Nov;66(11):1630-5.
  • Kresel JJ, Hutchings HC, MacKay DN, Weinstein MC, Read JL, Taylor-Halvorsen K, Ashley H.Application of decision analysis to drug selection for formulary addition.Hosp Formul. 1987 Jul;22(7):658-63, 673, 676.
  • Murphy JM, Berwick DM, Weinstein MC, Borus JF, Budman SH, Klerman GL.Performance of screening and diagnostic tests. Application of receiver operating characteristic analysis.Arch Gen Psychiatry. 1987 Jun;44(6):550-5.
  • Weinstein MC, Read JL, MacKay DN, Kresel JJ, Ashley H, Halvorsen KT, Hutchings HC.Cost-effective choice of antimicrobial therapy for serious infections.J Gen Intern Med. 1986 Nov-Dec;1(6):351-63.
  • Weinstein MC.Challenges for cost-effectiveness research.Med Decis Making. 1986 Oct-Dec;6(4):194-8.
  • Stern RS, Weinstein MC, Baker SG.Risk reduction for nonmelanoma skin cancer with childhood sunscreen use.Arch Dermatol. 1986 May;122(5):537-45.
  • Doubilry P, Weinstein MC, McNeil BJ.Forum: Use and misuse of the term "cost-effective".Health Cost Manage. 1986 May-Jun;3(3):11-6.
  • Doubilet P, Weinstein MC, McNeil BJ.Use and misuse of the term "cost effective" in medicine.N Engl J Med. 1986 Jan 23;314(4):253-6.
  • Sandberg SI, Barnes BA, Weinstein MC, Braun P.Elective hysterectomy. Benefits, risks, and costs.Med Care. 1985 Sep;23(9):1067-85.
  • Berwick DM, Weinstein MC.What do patients value? Willingness to pay for ultrasound in normal pregnancy.Med Care. 1985 Jul;23(7):881-93.
  • Doubilet P, McNeil BJ, Weinstein MC.The decision concerning coronary angiography in patients with chest pain. A cost-effectiveness analysis.Med Decis Making. 1985 Fall;5(3):293-309.
  • Weinstein MC, Stason WB.Cost-effectiveness of interventions to prevent or treat coronary heart disease.Annu Rev Public Health. 1985;6:41-63.
  • Hiatt HH, Weinstein MC.Will disease prevention spare the medical commons?.Ciba Found Symp. 1985;110:218-35.
  • Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ.Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach.Med Decis Making. 1985 Summer;5(2):157-77.
  • Weinstein MC.Methodologic considerations in planning clinical trials of cost-effectiveness of magnetic resonance imaging ... with a commentary on Guyatt and Drummond.Int J Technol Assess Health Care. 1985;1(3):567-81.
  • Dichter CR, Weinstein MC.Cost-effectiveness of lowering the aflatoxin tolerance level.Food Chem Toxicol. 1984 Jun;22(6):439-45.
  • Read JL, Quinn RJ, Berwick DM, Fineberg HV, Weinstein MC.Preferences for health outcomes. Comparison of assessment methods.Med Decis Making. 1984;4(3):315-29.
  • Weinstein MC.Cancer Prevention: Setting Priorities.Science. 1983 Dec 9;222(4628):1074-1077.
  • Weinstein MC, Schiff I.Cost-effectiveness of hormone replacement therapy in the menopause.Obstet Gynecol Surv. 1983 Aug;38(8):445-55.
  • Weinstein MC.Cost-effective priorities for cancer prevention.Science. 1983 Jul 1;221(4605):17-23.
  • Doubilet P, McNeil BJ, Weinstein MC.Optimal strategies for the diagnosis and treatment of coronary artery disease. Analysis using microcomputer.Med Decis Making. 1983;3(1):23-8.
  • Weinstein MC, Stason WB.Cost-effectiveness of coronary artery bypass surgery.Circulation. 1982 Nov;66(5 Pt 2):III56-66.
  • Berwick DM, Fineberg HV, Weinstein MC.When doctors meet numbers.Am J Med. 1981 Dec;71(6):991-8.
  • Pliskin JS, Stason WB, Weinstein MC, Johnson RA, Cohn PF, McEnany MT, Braun P.Coronary artery bypass graft surgery: clinical decision making and cost-effectiveness analysis.Med Decis Making. 1981;1(1):10-28.
  • Weinstein MC.Economic assessments of medical practices and technologies.Med Decis Making. 1981;1(4):309-30.
  • Koplan JP, Fraser DW, Schoenbaum SC, Weinstein MC.Benefits and risks of pertussis vaccine: further comments.N Engl J Med. 1980 Nov 27;303(22):1301-2.
  • Weinstein MC.Estrogen use in postmenopausal women--costs, risks, and benefits.N Engl J Med. 1980 Aug 7;303(6):308-16.
  • Weinstein MC.Cost-effectiveness analysis for clinical procedures in oncology.Bull Cancer. 1980;67(5):491-500.
  • Koplan JP, Schoenbaum SC, Weinstein MC, Fraser DW.Pertussis vaccine--an analysis of benefits, risks and costs.N Engl J Med. 1979 Oct 25;301(17):906-11.
  • Laird NM, Weinstein MC, Stason WB.Sample-size estimation: a sensitivity analysis in the context of a clinical trial for treatment of mild hypertension.Am J Epidemiol. 1979 Apr;109(4):408-19.
  • Weinstein MC.Prevention that pays for itself.N Engl J Med. 1978 Aug 10;299(6):307-8.
  • Weinstein MC, Stason WB.Economic considerations in the management of mild hypertension.Ann N Y Acad Sci. 1978 Mar 30;304:424-40.
  • Gillum RF, Stason WB, Weinstein MC.Screening for hypertension: a rational approach.J Community Health. 1978 Fall;4(1):67-72.
  • Weinstein MC, Stason WB.Allocating resources: the case of hypertension.Hastings Cent Rep. 1977 Oct;7(5):24-9.
  • Weinstein MC, Stason WB.Foundations of cost-effectiveness analysis for health and medical practices.N Engl J Med. 1977 Mar 31;296(13):716-21.
  • Stason WB, Weinstein MC.Public-health rounds at the Harvard School of Public Health. Allocation of resources to manage hypertension.N Engl J Med. 1977 Mar 31;296(13):732-9.
  • Weinstein MC.Allocation of subjects in medical experiments.N Engl J Med. 1974 Dec 12;291(24):1278-85.